MKI67 and breast cancer: The objectives of this study were to evaluate the distribution of Ki-67 testing status (yes vs no) and Ki-67 expression status (< 20% vs ≥20%) in patients with HR+, HER2− early breast cancer, highlighting patients with 1–3 involved lymph nodes, as well as the patterns of treatment in these patients.